logo

OCGN

Ocugen
--
--(--)
Market Open: --
--
--(--)
Post-Market: --

OCGN fundamentals

Ocugen (OCGN) released its earnings on May 9, 2025: revenue was 1.48M (YoY +46.53%), beat estimates; EPS was -0.05 (YoY 0.00%), beat estimates.
Revenue / YoY
1.48M
+46.53%
EPS / YoY
-0.05
0.00%
Report date
May 9, 2025
OCGN Earnings Call Summary for Q1,2025
  • 3 Pipeline Milestones: OCU400 (BLA 2026), OCU410ST (BLA 2027), OCU410 (BLA 2028) on track for 3 BLA filings by 2028.
  • Clinical Success: OCU400 Phase 1/2 shows 100% treated eyes improved; OCU410ST Phase 1 shows 54% slower lesion growth.
  • Financial Position: $38.1M cash, runway to Q1 2026; R&D spend up 40% to $9.5M reflecting clinical acceleration.
  • Manufacturing Scale: Malvern GMP facility ready for US launch 2027; process validation on track for 2025.
EPS
Revenue

Revenue & Expenses

OCGN has released its 2025 Q1 earnings report, with revenue of 1.48M, reflecting a YoY change of 46.06%, and net profit of -15.35M, showing a YoY change of -28.73%. The Sankey diagram below clearly presents OCGN's revenue sources and cost distribution.

Key Indicators

Ocugen (OCGN) key financial stats and ratios, covering profitability, financial health, and leverage.
Ocugen (OCGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Ocugen (OCGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Ocugen (OCGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Ocugen (OCGN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Ocugen (OCGN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield